Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Ira Pastor. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Ira Pastor or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Dr. Carina Kern - CEO, LinkGevity - Necrosis Inhibitors To Pause The Diseases Of Aging

55:03
 
Share
 

Manage episode 520899184 series 2835025
Content provided by Ira Pastor. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Ira Pastor or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

Send us a text

Dr. Carina Kern, Ph.D. is the CEO of LinkGevity ( https://www.linkgevity.com/ ), an AI-powered biotech company driving innovation in drug discovery for aging and resilience loss.
Dr. Kern has developed a new Blueprint Theory of Aging, which takes an integrative approach to understanding aging, combining evolutionary theory, genetics, molecular mechanisms and medicine, and is used to structure LinkGevity’s AI.
Dr. Kern’s labs are based at the Babraham Research Campus, affiliated with the University of Cambridge and her research has led to the development of a first-in-class necrosis inhibitor targeting cellular degeneration (Anti-Necrotic™). This novel therapeutic is ready to begin Phase II clinical trials later this year, as a potential breakthrough treatment for aging, with UK Government, Francis Crick Institute KQ labs, and European Union (Horizon) support.
The Anti-Necrotic™ has also been selected as one of only 12 global innovations for NASA’s Space-Health program, recognizing its potential to mitigate accelerated aging in astronauts on long-duration space missions.
Dr. Kern has held academic and leadership roles in interdisciplinary networks, including serving as President of the London Evolutionary Research Network and Co-Chair of the CleanTech Business Challenge, an initiative co-led by University College London and the London Business School.
Dr. Kern completed her PhD at UCL Institute of Healthy Ageing.
#CarinaKern #LinkGevity #BlueprintTheoryOfAging #BiologicalResilience #UniversityOfCambridge #BabrahamResearchCampus #CellularDegeneration #NecrosisInhibitor #AntiNecrotic #CaenorhabditisElegans #UCLInstituteOfHealthyAgeing #Senescence #Apoptosis #CellDeath #Necroptosis #Pyroptosis #Ferroptosis #PathoPathways #Gerotherapeutics #RyanodineReceptorInhibitors #CellPermeantCalciumChelators #LINK001 #AcuteKidneyInjury #SpaceMedicine #Exposome #Longevity
#ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #Research

Support the show

  continue reading

726 episodes

Artwork
iconShare
 
Manage episode 520899184 series 2835025
Content provided by Ira Pastor. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Ira Pastor or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

Send us a text

Dr. Carina Kern, Ph.D. is the CEO of LinkGevity ( https://www.linkgevity.com/ ), an AI-powered biotech company driving innovation in drug discovery for aging and resilience loss.
Dr. Kern has developed a new Blueprint Theory of Aging, which takes an integrative approach to understanding aging, combining evolutionary theory, genetics, molecular mechanisms and medicine, and is used to structure LinkGevity’s AI.
Dr. Kern’s labs are based at the Babraham Research Campus, affiliated with the University of Cambridge and her research has led to the development of a first-in-class necrosis inhibitor targeting cellular degeneration (Anti-Necrotic™). This novel therapeutic is ready to begin Phase II clinical trials later this year, as a potential breakthrough treatment for aging, with UK Government, Francis Crick Institute KQ labs, and European Union (Horizon) support.
The Anti-Necrotic™ has also been selected as one of only 12 global innovations for NASA’s Space-Health program, recognizing its potential to mitigate accelerated aging in astronauts on long-duration space missions.
Dr. Kern has held academic and leadership roles in interdisciplinary networks, including serving as President of the London Evolutionary Research Network and Co-Chair of the CleanTech Business Challenge, an initiative co-led by University College London and the London Business School.
Dr. Kern completed her PhD at UCL Institute of Healthy Ageing.
#CarinaKern #LinkGevity #BlueprintTheoryOfAging #BiologicalResilience #UniversityOfCambridge #BabrahamResearchCampus #CellularDegeneration #NecrosisInhibitor #AntiNecrotic #CaenorhabditisElegans #UCLInstituteOfHealthyAgeing #Senescence #Apoptosis #CellDeath #Necroptosis #Pyroptosis #Ferroptosis #PathoPathways #Gerotherapeutics #RyanodineReceptorInhibitors #CellPermeantCalciumChelators #LINK001 #AcuteKidneyInjury #SpaceMedicine #Exposome #Longevity
#ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #Research

Support the show

  continue reading

726 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play